Equillium
Biotechnology, Health Care, Science And Engineering · 35 employees
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.
Funding history
- Series private placement — $2.2M — Mar 2026
- Funding Round — $50.0M — Nov 2025
Recent signals
- Mar 13, 2026: Raised $2.2M in Series private placement
- Mar 11, 2026: SEC 8-K (1.01): On March 11, 2026, Equillium, Inc. entered into a Securities Purchase Agreement with RA Capital Healthcare Fund, L.P. in which they agreed to sell 1,179,508 shares of Common Stock at a price of $1.854 per share in a private placement. This agreement is a significant material definitive agreement as it involves substantial capital infusion for the company. The closing of the transaction is anticipated to occur on or about March 13, 2026, subject to customary conditions. The strategic implications of this agreement could enhance the company's financial position and support its operational objectives.
- Nov 13, 2025: Raised $50.0M
See plans & pricing → Track Equillium’s funding, hiring, and signals — with verified contacts — on Fundz.